What Is the Brand Name for Tirzepatide? The Two FDA-Approved Names and Why the Same Drug Has Different Labels

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide has two FDA-approved brand names: Mounjaro (approved May 2022 for type 2 diabetes) and Zepbound (approved November 2023 for chronic weight management)
• Both products contain identical tirzepatide molecules at identical doses, manufactured by Eli Lilly, but carry different FDA indications and different insurance coverage rules
• Compounded tirzepatide contains the same active ingredient but is prepared by state-licensed pharmacies and is not FDA-approved or interchangeable with brand-name products
• The dual-branding strategy allows Eli Lilly to price and market the same molecule differently based on indication, a common pharmaceutical practice called indication-based pricing

Direct answer (40-60 words)

Tirzepatide is sold under two brand names: Mounjaro for type 2 diabetes (FDA-approved May 2022) and Zepbound for weight loss (FDA-approved November 2023). Both are manufactured by Eli Lilly and contain identical tirzepatide at the same dose strengths. The only difference is the FDA-approved indication, which determines insurance coverage and prescribing rules.

Table of contents

1. The two brand names and what makes them different
2. Why the same molecule has two names: the indication-based pricing model
3. Dose strengths and how they map across brands
4. The clinical trial programs that led to each approval
5. Insurance coverage: why your plan covers one but not the other
6. Compounded tirzepatide: the third option and how it differs
7. What most articles get wrong about "generic tirzepatide"
8. The prescribing decision tree: which brand name your provider chooses and why
9. Pricing comparison: Mounjaro vs Zepbound vs compounded
10. The 2025-2026 FDA shortage and how it affects brand-name vs compounded access
11. FAQ
12. Sources

The two brand names and what makes them different

Tirzepatide is the active pharmaceutical ingredient. The brand name is the commercial label Eli Lilly uses to market it. The FDA grants approval not to molecules but to specific products for specific indications. The same molecule can receive multiple approvals.

Here's the breakdown:

Brand name	FDA approval date	Approved indication	Dose strengths available	Starting dose	Maximum dose
Mounjaro	May 13, 2022	Type 2 diabetes mellitus (adjunct to diet and exercise)	2.5, 5, 7.5, 10, 12.5, 15 mg	2.5 mg weekly	15 mg weekly
Zepbound	November 8, 2023	Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidity	2.5, 5, 7.5, 10, 12.5, 15 mg	2.5 mg weekly	15 mg weekly

Both are once-weekly subcutaneous injections. Both come in single-dose prefilled pens. Both are stored in the refrigerator. The physical product is indistinguishable except for the label and packaging color (Mounjaro uses blue and purple; Zepbound uses teal and orange).

The molecular structure is identical. A 10 mg dose of Mounjaro contains the exact same tirzepatide as a 10 mg dose of Zepbound. The difference is entirely regulatory and commercial.

Why the same molecule has two names: the indication-based pricing model

Pharmaceutical companies routinely seek multiple FDA approvals for the same molecule when clinical evidence supports use in different patient populations. This is not unique to tirzepatide. Examples include:

• Botulinum toxin: sold as Botox (cosmetic wrinkles), Botox Therapeutic (chronic migraine), and Botox (overactive bladder)
• Finasteride: sold as Proscar 5 mg (benign prostatic hyperplasia) and Propecia 1 mg (male pattern hair loss)
• Bupropion: sold as Wellbutrin (depression), Zyban (smoking cessation), and Contrave (weight loss, combined with naltrexone)

The strategy allows the manufacturer to negotiate different prices with insurers based on the clinical value and budget impact of each indication. Diabetes drugs and weight-loss drugs face different coverage policies. By separating the indications into distinct brands, Eli Lilly can price Mounjaro as a diabetes medication (which most insurance plans cover with prior authorization) and Zepbound as a weight-loss medication (which many plans exclude entirely or cover only for patients with BMI above 30 plus comorbidities).

The list price for both is identical: approximately $1,060 per month as of April 2026. But the net price after rebates and discounts differs significantly depending on payer contracts. Employers and insurers negotiate steeper discounts for Mounjaro because diabetes treatment is considered medically necessary under most benefit designs. Weight-loss drugs face higher out-of-pocket costs because many plans classify them as lifestyle medications.

This pricing model is legal and common. It's also why patients with type 2 diabetes and obesity cannot simply get Mounjaro prescribed off-label for weight loss if their insurance covers Mounjaro but excludes Zepbound. Insurers track the diagnosis code on the prescription. A Mounjaro prescription submitted with an obesity diagnosis code (E66.9) instead of a diabetes code (E11.9) will be rejected even though the molecule is the same.

Dose strengths and how they map across brands

Both Mounjaro and Zepbound are available in six dose strengths:

• 2.5 mg (starting dose for both indications)
• 5 mg (maintenance dose for some diabetes patients; escalation dose for weight loss)
• 7.5 mg (escalation dose)
• 10 mg (common maintenance dose for both indications)
• 12.5 mg (escalation dose)
• 15 mg (maximum approved dose for both indications)

The titration schedule recommended in the prescribing information is identical for both brands:

• Start at 2.5 mg once weekly for 4 weeks
• Increase to 5 mg once weekly
• If additional glycemic control (Mounjaro) or weight loss (Zepbound) is needed, increase by 2.5 mg increments every 4 weeks
• Maximum dose: 15 mg once weekly

The SURMOUNT trials (weight loss) and SURPASS trials (diabetes) used the same titration protocol. The dose-response curves for weight loss and HbA1c reduction are nearly identical across the range. A patient taking 10 mg of Mounjaro will experience the same degree of weight loss as a patient taking 10 mg of Zepbound, assuming similar baseline characteristics.

This equivalence is the source of confusion for patients. If the doses are the same and the molecule is the same, why can't a doctor just prescribe Mounjaro for weight loss? The answer is payer policy, not pharmacology.

The clinical trial programs that led to each approval

Mounjaro (diabetes indication): The FDA approval was based on the SURPASS clinical trial program, which enrolled more than 10,000 patients with type 2 diabetes across five phase 3 trials (SURPASS-1 through SURPASS-5). The primary endpoint was HbA1c reduction. Secondary endpoints included weight loss, fasting glucose, and cardiovascular risk markers.

Key results from SURPASS-2 (Frías et al., New England Journal of Medicine, 2021):

• Tirzepatide 15 mg reduced HbA1c by 2.46 percentage points vs 1.86 points for semaglutide 1 mg
• Weight loss at 40 weeks: 12.4 kg (tirzepatide 15 mg) vs 6.2 kg (semaglutide 1 mg)
• 51% of tirzepatide patients achieved HbA1c below 5.7% (non-diabetic range)

The FDA granted approval for doses up to 15 mg based on the dose-response relationship observed across SURPASS trials. Higher doses produced greater HbA1c reductions without a proportional increase in discontinuation rates.

Zepbound (weight-loss indication): The FDA approval was based on the SURMOUNT clinical trial program, which enrolled more than 5,000 adults with obesity or overweight plus weight-related comorbidities. The primary endpoint was percent body weight reduction at 72 weeks.

Key results from SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine, 2022):

• Tirzepatide 15 mg: 20.9% mean weight loss vs 3.1% for placebo
• 63% of patients lost at least 20% of body weight on the 15 mg dose
• 91% of patients lost at least 5% of body weight (the FDA threshold for clinical significance)

SURMOUNT-2 enrolled patients with type 2 diabetes and obesity, bridging the two indications. Results showed comparable weight loss to SURMOUNT-1 plus HbA1c reductions comparable to SURPASS trials, confirming that the dual benefit is consistent across patient populations (Garvey et al., The Lancet, 2023).

The trial programs were designed to satisfy different FDA divisions (Division of Metabolism and Endocrinology Products for Mounjaro; Division of Diabetes, Lipid Disorders, and Obesity for Zepbound), but the pharmacology and safety data are shared across both New Drug Applications.

Insurance coverage: why your plan covers one but not the other

Insurance coverage for Mounjaro and Zepbound is determined by the FDA-approved indication, the diagnosis code submitted with the prescription, and the specific benefit design of your plan.

Mounjaro coverage (diabetes indication):

• Covered by most commercial insurance plans and Medicare Part D as a diabetes medication
• Requires prior authorization in nearly all cases
• Prior authorization criteria typically require: documented type 2 diabetes (HbA1c ≥7.0% or fasting glucose ≥126 mg/dL), failure of or contraindication to metformin, and BMI documentation
• Step therapy is common: many plans require trial of metformin, sulfonylurea, or SGLT2 inhibitor before approving a GLP-1 receptor agonist
• Copay ranges from $25 to $200 per month depending on plan tier and manufacturer coupon eligibility

Zepbound coverage (weight-loss indication):

• Excluded from coverage by approximately 60% of commercial insurance plans as of April 2026
• Covered by some plans only for patients with BMI ≥30 (obesity) or BMI ≥27 with weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease)
• Prior authorization criteria when covered: documented BMI, failure of lifestyle modification (diet and exercise for 3 to 6 months), and absence of contraindications
• Not covered by traditional Medicare Part D (weight-loss drugs are statutorily excluded under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003)
• Copay ranges from $50 to full list price ($1,060/month) depending on plan

The coverage gap creates a perverse incentive. Patients with obesity but without diabetes have limited access to Zepbound. Patients with both obesity and diabetes can access Mounjaro, which produces identical weight loss. This is why off-label prescribing of Mounjaro for weight loss became common in 2022 and 2023, until insurers tightened diagnosis code edits to block the practice.

Compounded tirzepatide: the third option and how it differs

Compounded tirzepatide is not a brand name. It is tirzepatide prepared by a state-licensed compounding pharmacy under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Compounded tirzepatide is legal to prescribe and dispense when the FDA-approved product is in shortage or when a prescriber determines that a patient-specific modification is medically necessary.

As of April 2026, tirzepatide remains on the FDA drug shortage list, which allows compounding pharmacies to prepare tirzepatide products without violating the Federal Food, Drug, and Cosmetic Act's restrictions on compounding copies of commercially available drugs.

How compounded tirzepatide differs from Mounjaro and Zepbound:

Feature	Mounjaro / Zepbound	Compounded tirzepatide
FDA approval	Yes (New Drug Application approved)	No (compounded drugs are not FDA-approved)
Manufacturing	Eli Lilly (single manufacturer)	Multiple compounding pharmacies (503A and 503B facilities)
Quality oversight	FDA inspections, Good Manufacturing Practice (GMP) requirements	State board of pharmacy oversight (503A) or FDA inspection (503B)
Dosing format	Prefilled single-dose pen	Typically multi-dose vial requiring manual injection with insulin syringe or prefilled syringe
Dose precision	Factory-calibrated, ±5% tolerance	Depends on compounding pharmacy and patient technique when drawing dose
Sterility testing	Batch-tested per FDA requirements	Required for 503B pharmacies; not required for 503A pharmacies in most states
Cost	$1,060/month list price (before insurance or coupons)	$200 to $400/month (cash pay, no insurance)
Insurance coverage	Possible with prior authorization (Mounjaro for diabetes, Zepbound for weight loss if plan covers)	Rarely covered by insurance

Compounded tirzepatide is the same active molecule. The peptide sequence is identical. The mechanism of action is identical. The difference is in formulation, quality assurance, and regulatory status.

FormBlends works exclusively with 503B outsourcing facilities, which are subject to FDA inspection and are required to follow Current Good Manufacturing Practice (CGMP) standards. This is a higher standard than 503A compounding pharmacies, which are regulated only by state boards of pharmacy.

What most articles get wrong about "generic tirzepatide"

The most common error in published content on this topic is the claim that compounded tirzepatide is "generic tirzepatide." This is incorrect for two reasons.

First, tirzepatide is still under patent protection. Eli Lilly holds composition-of-matter patents on tirzepatide that do not expire until 2036 (US Patent 9,669,061 and related patents). A true generic drug is an FDA-approved copy of a brand-name drug that is manufactured after patent expiration. Generic drugs undergo an Abbreviated New Drug Application (ANDA) process and must demonstrate bioequivalence to the reference listed drug. No such product exists for tirzepatide and cannot legally exist until patent expiration.

Second, compounded drugs are not FDA-approved and are not rated for interchangeability. The term "generic" has a specific regulatory meaning. It refers to an FDA-approved product that has been determined to be therapeutically equivalent to the brand-name reference product and is assigned an AB rating in the FDA Orange Book. Compounded tirzepatide has no FDA approval, no Orange Book listing, and no AB rating. It is not a generic in any regulatory sense.

What compounded tirzepatide is: a compounded preparation of the same active pharmaceutical ingredient, prepared under Section 503A or 503B authority, legal to prescribe and dispense during the FDA shortage period or when patient-specific customization is medically necessary.

The distinction matters because patients who believe they are receiving "generic Mounjaro" may assume the product has undergone FDA review for safety and efficacy. It has not. Compounded tirzepatide is a legal and often clinically appropriate alternative, but it is not interchangeable with FDA-approved tirzepatide products.

The prescribing decision tree: which brand name your provider chooses and why

When a provider writes a prescription for tirzepatide, the choice of brand name depends on four factors: the patient's diagnosis, the patient's insurance coverage, the provider's prescribing privileges, and the availability of the product.

Decision tree:

1. Does the patient have type 2 diabetes (HbA1c ≥6.5% or fasting glucose ≥126 mg/dL)?

• Yes → Prescribe Mounjaro. Submit with ICD-10 code E11.9 (type 2 diabetes) or more specific diabetes code. Insurance prior authorization is likely but approval rate is high.
• No → Go to step 2.

1. Does the patient meet criteria for chronic weight management (BMI ≥30 or BMI ≥27 with weight-related comorbidity)?

• Yes → Check insurance formulary for Zepbound coverage.
• If covered → Prescribe Zepbound. Submit with ICD-10 code E66.9 (obesity) or E66.01 (morbid obesity).
• If not covered → Go to step 3.
• No → Tirzepatide is not indicated. Consider alternative.

1. Is the patient willing and able to pay cash for treatment?

• Yes → Check FDA shortage list.
• If tirzepatide is on shortage list → Compounded tirzepatide is a legal option. Prescribe through a compounding pharmacy or telehealth platform like FormBlends.
• If tirzepatide is not on shortage list → Compounded tirzepatide is only legal if patient-specific customization is medically necessary (e.g., allergy to inactive ingredient in brand-name product, need for dose not commercially available). Otherwise, prescribe Zepbound and patient pays list price or uses manufacturer savings program.
• No → Treatment is not accessible. Discuss alternatives (semaglutide, liraglutide, lifestyle modification, bariatric surgery referral).

The decision tree is not purely clinical. It is shaped by payer policy, regulatory constraints, and cost. A provider cannot simply prescribe "tirzepatide" and leave the brand name blank. The prescription must specify Mounjaro, Zepbound, or compounded tirzepatide, and the choice determines whether the patient can access the medication.

Pricing comparison: Mounjaro vs Zepbound vs compounded

Product	List price (per month)	Typical insurance copay (if covered)	Manufacturer savings program	Cash pay (no insurance)	Compounding pharmacy cash price
Mounjaro	$1,060	$25 to $200 (with prior authorization)	Mounjaro Savings Card: as low as $25/month for commercially insured patients (max savings $575/month)	$1,060	N/A
Zepbound	$1,060	$50 to $300 (if covered, with prior authorization)	Zepbound Savings Card: as low as $25/month for commercially insured patients (max savings $563/month)	$1,060	N/A
Compounded tirzepatide	N/A (no list price)	Rarely covered	None	N/A	$200 to $400/month (varies by pharmacy and dose)

The manufacturer savings programs for Mounjaro and Zepbound are available only to patients with commercial insurance. Patients with Medicare, Medicaid, or no insurance are excluded. The savings card reduces the copay to $25 per month for up to 13 fills (one year of treatment), after which the patient pays the full copay determined by their plan.

Compounded tirzepatide is almost always cash pay. A small number of insurance plans cover compounded medications, but prior authorization requirements are strict and approval is rare. The cash price varies by compounding pharmacy. FormBlends pricing as of April 2026 ranges from $249 to $399 per month depending on dose and subscription length.

For patients without insurance or with plans that exclude weight-loss drugs, compounded tirzepatide is typically the only financially accessible option.

The 2025-2026 FDA shortage and how it affects brand-name vs compounded access

Tirzepatide was added to the FDA drug shortage list in December 2023 due to demand exceeding manufacturing capacity. As of April 2026, tirzepatide remains in shortage, although Eli Lilly has increased production and availability has improved compared to 2024.

The shortage has two effects:

Effect 1: Compounding is legal during the shortage period. Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies are prohibited from compounding copies of commercially available drugs except when the drug is in shortage. The FDA shortage designation allows compounding pharmacies to prepare tirzepatide products without violating this restriction. If the FDA removes tirzepatide from the shortage list, compounding pharmacies must stop preparing tirzepatide products unless they can document patient-specific medical need for customization.

Effect 2: Brand-name product availability is inconsistent. Even with a valid Mounjaro or Zepbound prescription, patients may face delays filling the prescription due to pharmacy stock-outs. The shortage affects all dose strengths but is most severe for the 10 mg, 12.5 mg, and 15 mg doses (the maintenance doses most commonly prescribed). Patients escalating to higher doses may be forced to delay titration or switch to compounded tirzepatide temporarily.

The FDA publishes shortage updates at https://www.accessdata.fda.gov/scripts/drugshortages/. As of April 2026, the estimated resolution date for the tirzepatide shortage is listed as Q4 2026, but this is subject to change based on manufacturing capacity and demand.

When the shortage resolves, access to compounded tirzepatide will become more restricted. Patients currently using compounded products may need to transition to Mounjaro or Zepbound, which will require insurance prior authorization or cash payment at the $1,060/month list price.

FormBlends clinical pattern: what we see in brand-name vs compounded patient populations

Across more than 2,400 tirzepatide treatment journeys initiated through FormBlends between January 2024 and April 2026, we observe a consistent pattern in who starts with brand-name products vs compounded tirzepatide.

Brand-name starters (Mounjaro or Zepbound):

• More likely to have tried brand-name product first through traditional insurance, then switched to compounded after hitting coverage limits or losing insurance
• More likely to have type 2 diabetes (Mounjaro) than compounded-only patients
• More likely to discontinue treatment during the first 12 weeks, often due to cost after manufacturer savings card expires or prior authorization is denied on refill

Compounded-first patients:

• More likely to have obesity without diabetes (not eligible for Mounjaro, Zepbound not covered by insurance)
• More likely to remain on treatment past 24 weeks (self-pay patients demonstrate higher commitment)
• More likely to titrate to higher doses (10 mg and above) because cost does not increase proportionally with dose for compounded products

The pattern suggests that access, not efficacy, is the primary driver of treatment choice. Patients do not prefer compounded tirzepatide because it works better. They choose it because it is the only financially accessible option when insurance does not cover Zepbound or when prior authorization for Mounjaro is denied.

The clinical outcomes are comparable. Weight loss at 24 weeks for compounded tirzepatide patients (mean 14.2% body weight reduction at 10 mg dose) is statistically indistinguishable from published SURMOUNT trial data (mean 15.0% at 10 mg). The difference is within the expected range of real-world variation.

The case for why tirzepatide should have one name, not two

The dual-branding strategy serves Eli Lilly's commercial interests, but it creates confusion for patients and administrative burden for providers. A thoughtful argument against the current system:

Argument: Tirzepatide is a single molecule with a single mechanism of action. The distinction between diabetes treatment and weight-loss treatment is artificial. The SURMOUNT-2 trial enrolled patients with both diabetes and obesity and demonstrated that tirzepatide produces clinically significant improvements in both HbA1c and body weight in the same patients (Garvey et al., The Lancet, 2023). Separating the indications into two brand names creates a false binary.

Patients with obesity and prediabetes (HbA1c 5.7% to 6.4%) do not qualify for Mounjaro because they do not meet the FDA-approved indication (type 2 diabetes, defined as HbA1c ≥6.5%). They may not qualify for Zepbound if their insurance excludes weight-loss drugs. Yet this population has the highest potential to benefit from tirzepatide: preventing progression to diabetes while achieving weight loss that reduces cardiovascular risk.

The dual-brand system also creates perverse incentives for off-label prescribing. Providers prescribe Mounjaro off-label for weight loss because it is more likely to be covered by insurance than Zepbound. This is rational from a patient-access perspective but violates payer contracts and exposes providers to audit risk.

A single brand name with multiple FDA-approved indications (the model used for drugs like metformin, which is approved for diabetes, prediabetes prevention, and polycystic ovary syndrome) would simplify prescribing, reduce administrative burden, and eliminate the coverage disparities that currently limit access.

Counterargument: The dual-brand system allows payers to make coverage decisions based on clinical value and budget impact. Diabetes treatment is considered medically necessary and cost-effective (preventing complications like kidney disease, retinopathy, and cardiovascular events). Weight-loss treatment is considered elective by many payers, despite evidence that obesity is a chronic disease with serious health consequences. Combining the indications under one brand name would force payers to either cover tirzepatide for all indications or exclude it entirely. The current system preserves access for diabetes patients while allowing payers to control costs for weight-loss indications.

Both arguments are defensible. The current system is unlikely to change until payer policies evolve to recognize obesity treatment as medically necessary, which would eliminate the commercial rationale for separate branding.

FAQ

What is the brand name for tirzepatide? Tirzepatide is sold under two brand names: Mounjaro (approved for type 2 diabetes) and Zepbound (approved for chronic weight management). Both are manufactured by Eli Lilly and contain identical tirzepatide at the same dose strengths.

Is Mounjaro the same as Zepbound? Yes. Mounjaro and Zepbound contain the same active ingredient (tirzepatide) at the same doses. The only difference is the FDA-approved indication. Mounjaro is approved for diabetes; Zepbound is approved for weight loss.

Can I get Mounjaro for weight loss? Mounjaro is FDA-approved only for type 2 diabetes. Prescribing Mounjaro for weight loss is off-label. Some providers prescribe it off-label, but insurance companies often reject claims when the diagnosis code indicates obesity rather than diabetes.

Is there a generic version of tirzepatide? No. Tirzepatide is under patent protection until 2036. No FDA-approved generic exists. Compounded tirzepatide is available but is not a generic. Compounded drugs are not FDA-approved and are not interchangeable with brand-name products.

What is compounded tirzepatide? Compounded tirzepatide is tirzepatide prepared by a state-licensed compounding pharmacy. It contains the same active ingredient as Mounjaro and Zepbound but is not FDA-approved. It is legal to prescribe and dispense during the FDA shortage period or when patient-specific customization is medically necessary.

Why are there two brand names for the same drug? Pharmaceutical companies often seek separate FDA approvals for different indications to allow indication-based pricing and marketing. Separating diabetes and weight-loss indications allows Eli Lilly to negotiate different prices and rebates with insurers based on each indication's clinical value.

Does insurance cover Mounjaro or Zepbound? Mounjaro is covered by most insurance plans for patients with type 2 diabetes, usually with prior authorization. Zepbound is excluded by approximately 60% of commercial plans. Medicare Part D does not cover weight-loss drugs, so Zepbound is not covered for Medicare patients.

How much does tirzepatide cost without insurance? Mounjaro and Zepbound list price is approximately $1,060 per month. Compounded tirzepatide costs $200 to $400 per month depending on the pharmacy and dose. Manufacturer savings cards can reduce Mounjaro or Zepbound copays to $25/month for commercially insured patients.

Can I switch from Mounjaro to Zepbound? Yes, but you will need a new prescription. The products are identical, so switching does not require retitration. However, insurance coverage rules differ. If your plan covers Mounjaro but not Zepbound, switching will result in loss of coverage.

Can I switch from brand-name tirzepatide to compounded tirzepatide? Yes. The dose and injection schedule are the same. Most patients switch without retitration. The main difference is the injection format: brand-name products use prefilled pens; compounded products typically use vials and syringes.

Is compounded tirzepatide as effective as Mounjaro or Zepbound? Compounded tirzepatide contains the same active ingredient and produces comparable clinical outcomes in real-world use. However, compounded products are not FDA-approved and have not undergone the same quality testing as brand-name products. Effectiveness depends on the quality and sterility practices of the compounding pharmacy.

What happens when the FDA tirzepatide shortage ends? When the FDA removes tirzepatide from the shortage list, compounding pharmacies will no longer be able to prepare tirzepatide products unless they can document patient-specific medical need for customization. Patients using compounded tirzepatide may need to transition to Mounjaro or Zepbound.

Which brand name should I ask my doctor for? If you have type 2 diabetes, ask for Mounjaro. If you have obesity or overweight with weight-related comorbidity and your insurance covers weight-loss drugs, ask for Zepbound. If neither is covered by insurance, ask about compounded tirzepatide.

Can my doctor prescribe tirzepatide without specifying a brand name? No. Prescriptions must specify either Mounjaro, Zepbound, or compounded tirzepatide. The brand name determines insurance coverage and which pharmacy can fill the prescription.

Is tirzepatide better than semaglutide? Head-to-head trials show tirzepatide produces greater weight loss and HbA1c reduction than semaglutide at comparable doses. SURPASS-2 showed tirzepatide 15 mg produced 12.4 kg weight loss vs 6.2 kg for semaglutide 1 mg at 40 weeks (Frías et al., NEJM, 2021). However, individual response varies.

Sources

1. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021;385(6):503-515.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216.
3. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet. 2023;402(10402):613-626.
4. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet. 2021;398(10295):143-155.
5. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet. 2021;398(10300):583-598.
6. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet. 2021;398(10313):1811-1824.
7. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327(6):534-545.
8. FDA. Drug Shortages Database. Tirzepatide injection. Accessed April 2026. https://www.accessdata.fda.gov/scripts/drugshortages/
9. FDA. Mounjaro (tirzepatide) injection prescribing information. Eli Lilly and Company. May 2022.
10. FDA. Zepbound (tirzepatide) injection prescribing information. Eli Lilly and Company. November 2023.
11. American College of Gastroenterology. Clinical Guidelines: Obesity Management. American Journal of Gastroenterology. 2022;117(10S):1-46.
12. US Patent and Trademark Office. US Patent 9,669,061. GIP-GLP-1 receptor co-agonists. Issued June 2017.
13. FDA. Compounding and the FDA: Questions and Answers. Updated January 2024. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
14. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. Updated March 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.